key: cord-0694287-eccf4dct authors: Péré, Hélène; Podglajen, Isabelle; Baillard, Jean-Louis; Bouassa, Ralph-Sydney Mboumba; Veyer, David; Bélec, Laurent title: Thermal inactivation and nucleic acid amplification-based testing for SARS-CoV-2 date: 2020-08-12 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104588 sha: 7a45c4a46b4ed06192e9a762875cbef29b928e38 doc_id: 694287 cord_uid: eccf4dct nan Recently, Pang and colleagues reported that thermal inactivation of clinical samples at +56°C adversely affected the efficiency of RT-PCR for SARS-CoV-2 detection, likely by disrupting the integrity of the SARS-CoV-2 RNA with subsequent risk of false negative results [1] . However, the impact of heat inactivation on nucleic acid amplification-based testing results remains controversial. Thus, Chen and colleagues reported that the inactivation by incubating sample at +56°C for 30 min had no significant effect on the detection of SARS-CoV-2 by real-time RT-PCR [2] . In April 2020, Abbott Molecular (Des Plaines, IL, USA) received emergency use authorization (EUA) approval from Food and Drug Administration (FAD), USA, for real-time RT-PCR test to detect SARS-CoV-2 RNA in clinical specimens from suspected COVID-19 J o u r n a l P r e -p r o o f 2 patients [3] . The RealTime SARS-CoV-2 assay (Abbott Molecular) amplifies target regions of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) genes. The assay is run on the automated Abbott m2000 SP/rt platform currently in use internationally by reference laboratories and university hospitals. The RealTime SARS-CoV-2 assay has been validated for clinical use, and with the high-throughput, fully automated Abbott m2000 SP/rt system, this assay will accelerate the pace of SARS-CoV-2 testing [4] . The instructions for use of the RealTime SARS-CoV-2 assay (Abbott Molecular; reference 09N77-095) do not give details on pre-analytical processing of samples, and only claims that all human sourced materials should be considered infectious and be handled using appropriate laboratory biosafety practices [3] . Iorder to provide protection of our laboratory staff, and in the absence of instruction for clinical specimen inactivation from the manufacturer, we investigated herein whether thermal inactivation could affect the results of viral detection using RealTime SARS-CoV-2 assay (Abbott Molecular). Georges Pompidou, Paris, France, were included in the study. All patients had a positive result of SARS-CoV-2 using Allplex™ 2019-nCoV Assay (Seegene, Seoul, Korea), a multiplex real-time PCR assay detecting E, RdRP and N coronavirus target genes. Study patients were divided into two groups: group I with E, RdRp and N genes Ct A total of 40 patients were prospectively included, 19 in group I and 21 in group II. All COVID-19 patients were further subjected to nasal swabbing, as described [5] . After sampling, nasal swab was placed in a 15 mL plastic tube containing 3 mL of physiological serum (NaCl 0.9%). SARS CoV-2 RNA was further detected in parallel in paired native and heat-inactivated nasal specimen using RealTime SARS-CoV-2 assay (Abbott Molecular) with Abbott m2000 SP/rt platform in a biosafety level (BSL)-2 virology lab, according to manufacturer's instructions. Heat incubation was carried out in water bath at +56°C for 30 minutes. The proportions of patients with positive PCR results by Abbott RealTime SARS-CoV-2 assay using non-inactivated and heat-inactivated samples were compared using the Wilcoxon matched-paired signed rank test. The differences between coronavirus RdRp and N genes Ct values were compared using the paired two-tailed Student's t test within each group and between groups using the Welch's t test assuming unequal variances. The study was exempted from informed consent application, according to the French public health code for non-interventional study (CSP, article L 1121-1.1; https://www.legifrance.gouv.fr/). Data analyses were carried out using anonymized database. The World Health Organization stressed the need that health laboratories adhere to strict biosafety practices when testing clinical specimens for SARS-CoV-2 (5). [6] . In addition to mandatory personal protective equipment in BSL-2 lab, the issue is still debated of viral inactivation before nucleic acid amplification test. In the present series, heat-inactivation of clinical specimen did not affect significantly the results of SARS-CoV-2 detection, despite very slight increase of Ct values and rare undetectability with few samples harboring low viral load after thermal inactivation. In conclusion, our observations point that heat-inactivation is a convenient and easy tool to address the biosafety issue when using the FDA-approved RealTime SARS-CoV-2 assay (Abbott Molecular), that should be recommended. All authors confirmed they have contributed to the intellectual content of this paper and have met Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads Inactivation of 2019 new coronary virus before quantitative real-time PCR testing Abbott RealTime SARS-CoV-2 Assay Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19) J-LB and IP performed the experiments, and collected data. LB, DV, IP and RSMB analyzed the data and generated the figure. HP and IP supervised this study. All authors wrote and edited the manuscript. No authors declared any potential conflicts of interest. Assistance Publique-Hôpitaux de Paris, Paris, France.